Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VVOS vs BVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BVS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

BVS Overall Winner 6-Pillar Tally: VVOS 0 – 6 BVS Matrix Metrics: VVOS 1 – 9 BVS

As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas BVS carries 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin).

  • Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. VVOS 36.4/100 SELL) and 0.85β · 74% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile BVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VVOS vs BVS
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13
BVS NASDAQ Head-to-Head Winner
Bioventus Inc. Class A Common Stock
Surgical & Medical Instruments & Apparatus
$9.88
-0.7% 1D
Market Cap $681.3M
TTM Revenue $586M
Forward P/E 11.1x
Beta / 30D Vol 0.85β · 74% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 64.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.4%), weak momentum, RSI 29
RSI-14: 28.8 · SMA20: $11.75 · SMA50: $12.81

6-Pillar Scorecard Institutional Category Breakdown (VVOS 0 – 6 BVS)

Columns: Metric · VVOS · BVS
1. Valuation Multiples BVS
Forward P/E N/M 11.1x
Trailing P/E N/M 12.3x
PEG Ratio N/M 1.20x
EV / Revenue 0.1x 1.5x
2. Growth & Scale BVS
Revenue Growth (YoY) +34.9% +2.7%
Earnings Growth (YoY) +0.0% +69.7%
TTM Revenue (USD) $21M $586M
Market Cap $1.9M $681.3M
3. Profitability & Quality BVS
Gross Margin 61.9% 68.7%
Operating Margin -107.9% 10.1%
Net Profit Margin -121.8% 9.8%
Return on Equity (ROE) -8585.3% 25.8%
4. Balance Sheet & Cash Flow BVS
Cash Generation (TTM) -$21M EBITDA $85M
Cash Flow Margin -99.3% EBITDA Mgn 14.5%
Net Cash / Leverage -8585.3% ROE $199M Net Debt (0.96x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BVS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile N/A (N/A) 448.1% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat BVS
OpEx & R&D Intensity N/A 58.6% of Rev ($343M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VVOS (1) vs BVS (9)
Institutional Metric VVOS BVS Criterion Row Edge
Market Capitalization
Scale
$1.9M $681.3M Larger Scale BVS
Trailing P/E Ratio
Valuation
N/M 12.3x Lower Multiple BVS
Forward P/E Ratio
Valuation
N/M 11.1x Lower Multiple BVS
Revenue Growth (YoY)
Growth
+34.9% +2.7% Higher Growth VVOS
Operating Margin (TTM)
Profitability
-107.9% 10.1% Higher Margin BVS
Net Profit Margin
Profitability
-121.8% 9.8% Higher Margin BVS
Return on Equity (ROE)
Capital Efficiency
-8585.3% 25.8% Higher ROE BVS
52-Week Range Position
Momentum
0% ($0–$3) 36% ($6–$16) Stronger Trend BVS
Beta / 30D Volatility
Risk Regime
1.70β · 111% Vol 0.85β · 74% Vol Lower Realized Risk BVS
Unified Institutional Score
Composite Signal
36.4 / 100 (SELL) 46.2 / 100 (HOLD) Higher Composite BVS
Trailing 12M Revenue (USD)
Operating Scale
$21M $586M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.9% 68.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev 1.20x PEG · 1.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M EBITDA (-8585.3% ROE) $85M ($199M Net Debt (0.96x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BVS +24.94 pp
VVOS: -59.25% · BVS: -34.31%
3M Horizon BVS +50.96 pp
VVOS: -80.49% · BVS: -29.53%
6M Horizon BVS +97.62 pp
VVOS: -91.15% · BVS: +6.47%
1Y Horizon BVS +144.73 pp
VVOS: -97.71% · BVS: +47.02%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VVOS Revenue BVS Revenue VVOS Op. Margin BVS Op. Margin Margin Leader
FY2019 $10M $340M -92.8% 9.2% BVS
FY2020 $10M $320M -92.1% 6.6% BVS
FY2021 $20M $430M -120.7% 2.8% BVS
FY2022 $20M $510M -156.2% -32.7% BVS
FY2023 $10M $510M -125.3% -16.0% BVS
FY2024 $20M $570M -74.3% -2.7% BVS
FY2025 $20M $570M -114.1% 9.5% BVS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BVS BREAKDOWN
76d in phase · OBV DISTRIBUTION
Current IV 448.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BVS Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $681.3M market capitalization and 10.1% operating margin.
OpEx & R&D Reinvestment 58.6% of Rev ($343M)
90D Engineering Disclosures 0 Published

Investor FAQ VVOS vs BVS Key Questions & Quantitative Answers

As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas BVS carries 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin). Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. VVOS 36.4/100 SELL) and 0.85β · 74% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile BVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BVS leads the Growth & Scale pillar: VVOS posts +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin), compared with BVS at +2.7% YoY revenue growth and +69.7% YoY earnings growth on $586M TTM revenue (68.7% gross margin, 10.1% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), VVOS cumulative revenue shifted +100.0% while BVS shifted +67.6%. In operating R&D and SG&A reinvestment, VVOS deploys N/A (0 90-day corporate R&D disclosures) versus 58.6% of Rev ($343M) (0 disclosures) for BVS.

BVS screens cheaper on headline valuation multiples. VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin), whereas BVS trades at 11.1x Forward P/E, 12.3x Trailing P/E, 1.20x PEG, and 1.5x EV/Revenue (14.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VVOS (-8585.3% ROE) versus BVS (25.8% ROE) capital efficiency.

In options market volatility and institutional positioning, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk). By comparison, BVS carries 448.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.85β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.